United Therapeutics Corp. (UTHR) announced Monday morning that it received a second complete response letter from the FDA, declining to approve its new drug application for treprostinil diolamine extended release tablets, for the treatment of pulmonary arterial hypertension.
United Therapeutics gapped open sharply lower Monday, but recovered some ground in early trade, before settling into a range. The stock closed down by 1.33 at $59.62 on strong volume. Shares slipped to over a 3-week low.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.